Valuation: Geron Corporation

Market Cap 847M 741M 684M 639M 1.2B 80.05B 1.23B 8.22B 3.18B 39.49B 3.18B 3.11B 137B P/E 2026 *
-65.5x
P/E 2027 * 20.1x
Enterprise Value 826M 723M 667M 623M 1.17B 78.07B 1.2B 8.02B 3.1B 38.51B 3.1B 3.03B 134B EV / Sales 2026 *
3.53x
EV / Sales 2027 * 2.03x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-1.52%
1 week+3.17%
Current month+4.00%
1 month+4.00%
3 months-7.14%
6 months-5.11%
Current year-1.52%
1 week 1.28
Extreme 1.28
1.47
1 month 1.08
Extreme 1.08
1.47
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
20/05Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-1.52%+3.17%-12.75%-58.20% 847M
+0.13%+1.50%+63.86%+123.95% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+3.71%-11.68%-11.82% 23.07B
+1.32%+9.33%+5.28%+419.80% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+5.01%+31.23%-32.10% 15.94B
-0.89%+4.57%+24.30%+185.83% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +3.10%+6.63%+42.30%+115.88% 22.71B
Weighted average by Cap. +3.40%+7.61%+53.92%+128.22%

Financials

2026 *2027 *
Net sales 234M 205M 189M 176M 332M 22.1B 339M 2.27B 877M 10.9B 878M 858M 37.84B 333M 292M 269M 251M 473M 31.49B 484M 3.23B 1.25B 15.54B 1.25B 1.22B 53.93B
Net income -13.95M -12.21M -11.26M -10.53M -19.82M -1.32B -20.26M -135M -52.36M -651M -52.4M -51.25M -2.26B 46.55M 40.75M 37.57M 35.12M 66.12M 4.4B 67.58M 452M 175M 2.17B 175M 171M 7.54B
Net Debt -20.97M -18.36M -16.93M -15.82M -29.79M -1.98B -30.44M -204M -78.68M -978M -78.74M -77.01M -3.39B -169M -148M -136M -127M -240M -15.98B -245M -1.64B -634M -7.88B -635M -621M -27.36B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
29/06/26 USD 1.309 -0.83% 14,543,025
26/06/26 USD 1.320 -3.65% 36,634,117
25/06/26 USD 1.370 -1.08% 9,546,037
24/06/26 USD 1.385 +2.59% 19,234,596
23/06/26 USD 1.350 +0.75% 13,103,262
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.320USD
Average target price
3.400USD
Spread / Average Target
+157.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock